The journey of Dr. David Samadi dates back to Iranian Revolution in 1979 which made him and his brother leave his Persian Jewish community for Belgium and were separated from their parents. The revolution happened when he was 15 years and his brother Dan was 12 years. Away from their home, Iran, Dr. David, and Dan were forced to begin a life that they were not used to where they missed the presence of their sister, Heidi, and their parents.
The dream of David has always been to be a doctor hence he worked hard to achieve his goal. 6 months after their move to Belgium, the two brothers moved to north London and finally migrated to America in 1984 where they did their high school and consequent studies. Their life started taking shape when they came to New York, the United States where they excelled more in school especially in Sciences. Dr. David Samadi finished his first year with honors at Stony Brook School of Medicine by 1990.
Samadi later enrolled for his Master’s Degree at S.U.N.Y Stony Brook School of Medicine, New York and by 1994 he graduated. In 1996, he completed his postgraduate degree at Montefiore Medical Center and joined Albert Einstein College of Medicine for proctology training. Four years later, he completed the oncology fellowship majoring in proctology at Memorial Sloan Kettering Cancer Center. And over the years, Dr. David Samadi has been focusing on diagnosing and treating prostate cancer, bladder cancer, urologic diseases, and kidney cancer. This is very common diseases that are disturbing the minds of many, no wonder; many celebrate Dr. Samadi for his services.
Dr. David Samadi is one of the few unique surgeons in the United States who is specialized in Urologic Oncologic discipline who have been trained in all the three major areas of surgery which includes robotic, open and laparoscopic. He serves Medical Advisory Board at PinnacleCare International as an active member. He has founded Robotic Fellowship Program of Mount Sinai where he also serves as the Director.
Definitely, such a doctor and surgeon have received numerous awards and recognition from various magazines like New York Magazine which named him in the Best Doctor’s Issue in 2009. Besides him being a doctor, he is also a host on Fox News Channel of Sunday Housecall program which comes weekly. He also has a radio program called World Health News on am970 radio where he educates his listeners on matters of health.
For details: www.roboticoncology.com/
Healthcare costs in the United States are incredibly high, we all (hopefully) are aware of that fact. Yet, seeing the actual numbers on paper is truly staggering. According to a recent Forbes article,the latest costs come in at over $900 billion. The article cited that aging and population growth were a great driver in this number skyrocketing. However, the main cause was just plain higher charges and patient care becoming more expensive.
It seems like a no-brainer that if the medical community and insurance companies worked together those costs could be brought down. That isn’t likely to happen. In fact, the article even cited that it is the actual pricing structure of getting health care that is directly responsible for the nearly unbelievable cost of healthcare in the United States.
So, we are left with the healthcare system and the insurance companies at odds, and the loser is the American people. It seems that in order to bring about change we will need a huge disruptor in the healthcare field.
One such disruptor is Tempus, a company that merges healthcare and technology in order to build the largest library of clinical and molecular data that the world has ever seen. In addition to that library, they are using the latest technology to build a universally accessible operations system so that the collected data is immediately accessible to physicians across the globe. Tempus will specifically focus on cancer patients and will utilize a machine learning system that will enable physicians to create highly specialized cancer care treatment plans for each individual patient based on collected big data.
Tempus is the brainchild of Eric Lefkofsky. He is a leader in the technology sector in America and is based out of Chicago. Lefkofsky founded Tempus after noticing that cancer data was being collected for each patient but that there was no centralized system that housed that data and made it available to other physicians.
Outside of the technology sector, Lefkofsky has the Lefkofsky Family Foundation. One of the major goals of the Foundation is to propel highly innovative medical research. Through the launch of Tempus, Lefkofsky is bringing the innovation to life.
There are many different ways that doctors are able to learn about the things that they can do in their practices. This is something that has been common for decades and something that has truly made a difference in the way that people are able to do things. Because of the opportunities that people have when they are working in medicine, it is important that they publish the information that they find out so that other doctors will have a chance to learn more about the things they are doing and use them in their own practices. Doctors who can help each other out will always be more successful than doctors who do not know how to help each other and who do not have a platform from which they can learn more about treatment options in the different fields of medicine.
Oncotarget provides doctors with a place to truly connect with each other. Unlike mixers and things that can be detrimental for people who do not know what they are doing, Oncotarget is a research site that gives everyone the chances that they need to make sure that they are going to be able to have the best experience possible. Because of the way that the publication is set up and because of the options that doctors have when they are looking at the information, Oncotarget provides a place where doctors are able to make true connections with each other and learn the information that they have found through their various studies.
Not only is Oncotarget beneficial for doctors to be able to use but it is also a publication that those who are studying to become doctors can use. The publication has been beneficial because of the way that it has allowed people the chance to learn more about the different things that there are to do in medicine. People who are able to learn more about the things that are going on in medicine will be more likely to have a better experience in their medical career. It will allow them to make the right decisions and to grow the opportunities that they have.
The field of cancer therapies has received numerous contributions from different companies in the past ten years. However, Seattle Genetics has stood out in its course to undertake extensive cancer research. Through Seattle Genetics, Dr. Clay Siegall has made advancements in cancer therapy. The company’s dominance in this field is reflected in their stock price, which has tripled over the years. As the leader of Seattle Genetics, Clay Siegall is determined to change the lives of cancer patients. Through cutting-edge research developments, Siegall has seen the company develop the first antibody drug conjugates, ADCETRIS, which was approved by FDA in 2011.
Today, ADCETRIS is being sold in over 60 countries. Siegall is dedicated to promoting the drug in an effort to ensure that the biomedical community prioritizes cancer therapies in the coming years. His steadfast devotion to cancer therapy motivated him to push for the FDA approval. He remains optimistic that ADCETRIS will be made available to many patients around the world. He has played an instrumental role in enhancing company’s funding. Recently, he received more than $1.2 billion through public and private funding, which has enhanced their advancements in cancer treatments using the most innovative technologies.
Clay B. Siegall, PhD is a co-founder of Seattle Genetics. He serves as president, CEO and chairman of the Board. With a deep passion to improve the lives of cancer patients, Clay built Seattle Genetics on the foundation of thorough scientific research and drug development practices. The company has entered into numerous collaborator programs where they are now developing more than 20 ADCs using Seattle Genetics’ technology.
Before establishing Seattle Genetics, Siegall worked for different companies, including Bristol-Myers Squibb Pharmaceutical Research Institute, National Institutes of Health and the National Cancer Institute. He is a member of the boards of directors of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. His distinguished career has seen him earn recognition and several awards, including the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Clay is a committed author having over 70 publications. He is a graduate of George Washington University and the University of Maryland.